Track the companies that matter to you. It's FREE! Click one of these fan favorites to get started: Apple; Google; Ford.



3 Bad Reasons to Buy Chimera Now

Don't let it get away!

Keep track of the stocks that matter to you.

Help yourself with the Fool's FREE and easy new watchlist service today.

Let me be clear at the outset: I wouldn't recommend buying shares of Chimera Investment Corp. (NYSE: CIM  ) to my worst enemy -- oh wait, yes I would.

Anybody who's read my recent columns (like this one) knows full well what I think about this company. It hasn't published a single financial statement for over a year now, it's restating the lion's share of its previous filings due to a purported accounting error, and its CEO and CFO are both close relatives of executives and board members of its manager Annaly Capital Management (NYSE: NLY  ) .

That being said, I could be wrong. And it's in this vein that I'll grin, bear it, and offer three reasons that could entice an investor to buy shares in this unconscionably risky company.

1. It's undervalued
At the beginning of March, Chimera dropped a bombshell on its investors by announcing that it wouldn't file its 2011 annual report because "additional time is required ... to review the application of GAAP guidance to certain of its non-Agency assets."

If this wasn't bad enough, five months later, by which time it had also missed the deadline to file its report for the first quarter of 2012, it acknowledged that it will restate all quarterly and annual financial statements dating back to the third quarter of 2008.

And in the meantime, it's provided only the most cursory of updates to book value. Consequently, investors in the company have been left in the dark with respect to 90% of the company's existence.

While this is unquestionably a problem -- an inexcusable one in my opinion -- it nevertheless leaves significant room for mispricing, as investors know little to nothing about what's going on inside Chimera's portfolio of private-label mortgage-backed securities.

Between the first and second quarters of this year, for example, Chimera estimated that its economic book value increased from $2.76 per share to $2.87 per share. Meanwhile, it currently trades for $2.76 per share, a nearly 4% discount to its economic book value at the end of June -- the discount increases to almost 11% when GAAP book value is used as the denominator.

As a result, when it does announce, presumably by the middle of January to avoid being delisted by the New York stock Exchange, its shares could theoretically shoot up.

2. Its accounting problems are misunderstood
Make no mistake about it, the significance and tangible impact of Chimera's accounting problems will dictate the short-term price movements of its stock -- if not the company's continued viability. But despite the typical view of accounting as a cut-and-dry exercise in pencil-pushing, it's much more of an art than a science. This is why investors and analysts like myself could very well be misunderstanding the net effect of Chimera's purported accounting error.

There are two things to keep in mind, here. In its press release announcing the restatements, Chimera estimated that its net income would drop by two-thirds over the time period between the third quarter of 2008 and the third quarter of 2011 because of the deterioration in the value of its private-label mortgage-backed securities. That's significant! At the same time, however, according to Chimera, all of the changes will be balance-sheet neutral because it had already deducted the losses from its shareholders' equity account.

Consequently, once the restatements are published, and again assuming there's no tangible impact on its ability to continue operating, the cloud that's depressing Chimera's shares could be lifted, yielding an immediate appreciation in its share price.

3. It could be a takeover target
One company's trash is another company's treasure. What I mean by this is that the same private-label mortgage-backed securities causing Chimera so many accounting problems could be just what Annaly is looking for.

At the beginning of last month, Annaly submitted a bid to acquire Crexus Investment Corp. (UNKNOWN: CXS.DL.DL  ) , a much smaller REIT that specializes in commercial real estate assets. It did so because Annaly is diversifying away from increasingly low-yielding, agency-issued mortgage-backed securities. Not to mention, because Crexus is effectively debt free and already operating under the Annaly family of companies, its consolidation would be immediately accretive to the Annaly's bottom line. It's for these reasons that Annaly offered to pay a 13% premium to the Crexus' pre-announcement closing price.

Chimera comes into the equation because it shares many of the same characteristics as Crexus. It has a portfolio of higher-yielding non-agency securities that could be used to counterbalance Annaly's portfolio of agency securities. And it already operates under the Annaly umbrella, offering self-evident synergies. If Annaly were to pull the trigger, in turn, it would likely pay an analogous premium to where Chimera trades today.

These reasons aside, steer clear of this stock
Allow me to end this column on the same clear note that I began. These three reasons to buy Chimera are nothing more than pie-in-the-sky scenarios. That said, I wouldn't touch this stock with a ten-foot pole, and neither should you.

To see more reasons why this is so, or if you're even halfway thinking about buying stock in this company, I implore you to download our in-depth report on Chimera. To access a copy while it's still available, click here now.

Read/Post Comments (2) | Recommend This Article (8)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On December 14, 2012, at 4:20 PM, prginww wrote:

    Mr. Maxfield,

    Agree completely. I can't really see why anyone would give credence to the estimated figures when the required filings have been late, non-existent, or incorrect.

    I'm beginning to worry about NLY in this matter too. Comment?

  • Report this Comment On December 15, 2012, at 12:13 AM, prginww wrote:


    I'm not sure if this answers your question or not, but I see NLY and CIM as essentially the same entity when it comes to issues involving management, ethics, etc. This article talks a little more about this:


Add your comment.

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2154519, ~/Articles/ArticleHandler.aspx, 10/27/2016 3:47:06 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated 6 hours ago Sponsored by:
DOW 18,199.33 30.06 0.17%
S&P 500 2,139.43 -3.73 -0.17%
NASD 5,250.27 -33.13 -0.63%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

10/26/2016 4:00 PM
CIM $15.74 Down -0.03 -0.19%
Chimera Investment CAPS Rating: ***
AGNC $20.26 Up +0.08 +0.40%
American Capital A… CAPS Rating: ***
ARR $22.79 Down -0.15 -0.65%
ARMOUR Residential… CAPS Rating: ***
CXS.DL.DL $0.00 Down +0.00 +0.00%
CreXus Investment CAPS Rating: ***
NLY $10.41 Up +0.04 +0.39%
Annaly Capital Man… CAPS Rating: ****